Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
about
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle interventionBest of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FLActive surveillance for prostate cancer: current evidence and contemporary state of practiceBest of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.Pretreatment predictors of death from other causes in men with prostate cancer.Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.Outcomes of active surveillance for men with intermediate-risk prostate cancer.Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intentDelayed versus immediate surgical intervention and prostate cancer outcomeSelective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.Temporal changes in the pathologic assessment of prostate cancer.Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.Role of 5 alpha-reductase inhibitors in the management of prostate cancer.Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillanceRadical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionActive surveillance for favorable-risk prostate cancer: a short review.Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer.Early experience with active surveillance in low-risk prostate cancer treated.Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance.Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.Early outcomes of active surveillance for localized prostate cancer.Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.Conditional probability of reclassification in an active surveillance program for prostate cancerFactors predicting Gleason score 6 upgrading after radical prostatectomy.
P2860
Q24653994-72E6720A-B8EB-4A96-88F8-1B43E388021FQ24654903-F02EFD69-9895-4366-9528-64C20B66567EQ28066534-32A0A394-E01B-450F-A7D4-806B950BC64CQ33302509-8CEA1016-591B-4E0D-8534-48E872E18636Q33561172-DF32752D-68D0-4681-8CA3-31C2F2FFB479Q34076905-707F1D31-5D94-48AA-9001-AA1C29003611Q34151167-45318A44-338A-4688-BD20-DE3EA0EC7268Q34380870-9CC4FC9F-232A-412E-BB3B-1EAE43887338Q34454050-D3515853-4CAF-44A5-8D33-C22F0F9ADD1CQ34659767-5B0C0324-B932-4BCD-8C15-A2C63125A96EQ34679207-4504DC96-426C-4750-B225-96BD95F435FBQ35322578-F13144C5-267A-4974-B5A0-FB835D6C693AQ35685712-F2C61461-50FB-462D-836C-4D17164DC951Q35966831-CBA0E353-EC89-4923-A774-4C30C2498B4CQ36336991-DD9566B3-F132-4AF6-9045-3466381AB9BFQ36421154-FE583DD3-1E74-411C-9B9A-4F91675395C1Q36520474-17174583-581B-4CE4-B849-A2F572FF0DC7Q36524465-0F89E985-1146-4425-823F-535B29CAEE22Q37018960-8DF6BADB-D184-4BAC-B2EE-CE85F3675293Q37023829-01A1169E-C3F3-47D2-A1CC-01B3C188FE0AQ37029385-95227A29-D105-4739-98EB-18912A63173BQ37084366-40F50084-CCC8-4459-973C-CDB1CF7D8070Q37272887-5DF92B80-E42B-490D-B9EE-CFE05A486745Q37592409-8AA33E5C-C266-4E63-8F2C-FAD25F6005FCQ37598429-8FFE4D63-4DA9-46B4-BBB8-4BA0E7C04D10Q37685652-9F1AE3FC-1E9A-4449-88B7-CA20927CB333Q37689245-49D6334F-1279-4567-B7B5-81118C55E9BAQ37689254-300E9960-3168-4CFA-810D-903CB67B3186Q37700962-C7A20796-15AA-44E6-AA4A-7D12AF953F8AQ37804698-34E234FE-C9B9-41C0-B9FF-219EF160B93FQ38209526-CD308637-76CA-4FC4-97B3-9600B0A520CFQ38306089-61BC3C56-D671-443D-B699-8961E72E303AQ38392814-785D1519-A87D-42CC-AB12-6034121FC012Q38762709-8AB58DDA-7FDC-44F5-BA7E-78F7F53B8CE7Q39531223-5FB4B252-DC72-4278-9EE2-12E5ABACA50BQ39713992-A85D3E77-F351-47B9-A2CE-59D53D47B4DFQ39727032-D4345AC1-8600-455E-9905-74A807E98D0BQ40870014-6975C349-E923-4FE4-A610-808271F355BFQ41495208-05798F24-0E32-4132-89DE-F9CAD02E6DB3Q41948735-F1D2ACD1-FF1F-4D27-841F-9C911D623172
P2860
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Expectant management of nonpal ...... e intent: preliminary results.
@en
Expectant management of nonpal ...... e intent: preliminary results.
@nl
type
label
Expectant management of nonpal ...... e intent: preliminary results.
@en
Expectant management of nonpal ...... e intent: preliminary results.
@nl
prefLabel
Expectant management of nonpal ...... e intent: preliminary results.
@en
Expectant management of nonpal ...... e intent: preliminary results.
@nl
P2093
P1476
Expectant management of nonpal ...... e intent: preliminary results.
@en
P2093
H Ballentine Carter
Jonathan I Epstein
Patricia Landis
Patrick C Walsh
P304
P356
10.1097/00005392-200203000-00006
P407
P577
2002-03-01T00:00:00Z